Literature DB >> 2910092

Hypertriglyceridemia in the acquired immunodeficiency syndrome.

C Grunfeld1, D P Kotler, R Hamadeh, A Tierney, J Wang, R N Pierson.   

Abstract

PURPOSE: A relationship between the induction of hypertriglyceridemia by cytokines and the cachexia seen in chronic infection has been proposed by other investigators. Since patients with the acquired immunodeficiency syndrome (AIDS) often experience progressive tissue wasting, we decided to examine serum lipid levels and body cell mass in patients with AIDS. PATIENTS AND METHODS: Serum lipid levels and body cell mass were measured in 32 patients with the acquired immunodeficiency syndrome (AIDS), eight asymptomatic subjects who were anti-human immunodeficiency virus (HIV) antibody positive, and 17 heterosexual and homosexual control subjects who did not have antibodies to HIV.
RESULTS: Mean triglyceride concentrations and the prevalence of hypertriglyceridemia (50 percent) were significantly increased in patients with AIDS compared with control subjects (p less than 0.002 and p less than 0.005, respectively), whereas the mean triglyceride levels of HIV-positive subjects were intermediate. There were no differences in cholesterol levels among the three groups. Using total body potassium adjusted for height and age (KHT) as a measure of body cell mass, 16 of 32 patients with AIDS but none of the HIV-positive or control subjects had significant depletion of body cell mass. There was no direct relationship between triglyceride levels and KHT among AIDS or HIV-positive subjects. In patients with AIDS, mean triglyceride levels and the prevalence of hypertriglyceridemia were similar in the presence and absence of wasting.
CONCLUSION: Hypertriglyceridemia is a common finding in AIDS and is independent of the degree of wasting.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910092     DOI: 10.1016/0002-9343(89)90225-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  76 in total

1.  Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.

Authors:  Madhu N Rao; Grace A Lee; Carl Grunfeld
Journal:  Am J Infect Dis       Date:  2006-09-30

2.  Longevity on Antiretroviral Therapy for Children Living with HIV/AIDS--A Price to Pay for Success?

Authors:  Mamatha M Lala; Rashid H Merchant
Journal:  Indian J Pediatr       Date:  2016-02-06       Impact factor: 1.967

3.  A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects.

Authors:  Veera Venkata Ratnam Bandaru; Michelle M Mielke; Ned Sacktor; Justin C McArthur; Igor Grant; Scott Letendre; Linda Chang; Valerie Wojna; Carlos Pardo; Peter Calabresi; Sody Munsaka; Norman J Haughey
Journal:  Neurology       Date:  2013-09-11       Impact factor: 9.910

4.  Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.

Authors:  Colleen Hadigan; James Liebau; Martin Torriani; Rebecca Andersen; Steven Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

Review 5.  The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.

Authors:  Grace A Lee; Madhu N Rao; Carl Grunfeld
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

Review 6.  Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?

Authors:  David Nolan
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 7.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Authors:  Mustafa A Noor
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

Review 8.  Considering metabolic issues when initiating HIV therapy.

Authors:  David Alain Wohl
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

9.  HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation.

Authors:  Neeti Agarwal; Dinakar Iyer; Sanjeet G Patel; Rajagopal V Sekhar; Terry M Phillips; Ulrich Schubert; Toni Oplt; Eric D Buras; Susan L Samson; Jacob Couturier; Dorothy E Lewis; Maria C Rodriguez-Barradas; Farook Jahoor; Tomoshige Kino; Jeffrey B Kopp; Ashok Balasubramanyam
Journal:  Sci Transl Med       Date:  2013-11-27       Impact factor: 17.956

10.  Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study.

Authors:  Michelle C Odden; Rebecca Scherzer; Peter Bacchetti; Lynda Anne Szczech; Stephen Sidney; Carl Grunfeld; Michael G Shlipak
Journal:  Arch Intern Med       Date:  2007-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.